Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of “Buy” by Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have received a consensus rating of “Buy” from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $15.13.

CATX has been the topic of several recent analyst reports. Scotiabank initiated coverage on shares of Perspective Therapeutics in a report on Friday. They set a “sector outperform” rating and a $15.00 price objective on the stock. Oppenheimer lowered their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Finally, Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th.

Perspective Therapeutics Stock Performance

CATX opened at $2.61 on Monday. Perspective Therapeutics has a 52-week low of $2.32 and a 52-week high of $19.05. The firm’s 50-day moving average price is $3.21 and its 200-day moving average price is $7.66.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its holdings in Perspective Therapeutics by 221.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after acquiring an additional 298,778 shares during the period. WealthPlan Investment Management LLC purchased a new position in shares of Perspective Therapeutics in the 3rd quarter valued at about $4,530,000. State Street Corp boosted its stake in shares of Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after buying an additional 1,192,812 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after buying an additional 355,685 shares during the period. Finally, FMR LLC boosted its stake in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.